DALLAS, Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence
("A.I.") platform to transform the cost, pace, and timeline of
oncology drug discovery and development, today announced that
Panna Sharma, Chief Executive
Officer and President of Lantern Pharma, will be presenting at the
H.C. Wainwright BioConnect 2022 Conference being held virtually
January 10-13, 2022. The presentation
will be conducted as a fireside chat hosted by H.C. Wainwright
Senior Biotechnology Analyst and Managing Director, Michael King.
Lantern Pharma's presentation will be available on-demand to
registered attendees via the conference platform beginning
Monday, January 10, 2022 at
7:00 AM Eastern Time.
The webcast of the Company's presentation can be accessed here:
journey.ct.events and on the investor relations section of Lantern
Pharma's website at ir.lanternpharma.com as of 7:00 AM Eastern Time on Monday, January 10,
2022.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is
a clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eight disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and Twitter
@lanternpharma.
About RADR®
RADR® or
Response Algorithm for Drug Positioning &
Rescue, is Lantern's proprietary integrated A.I. platform
for large-scale biomarker and drug-tumor interaction data analytics
that leverages machine-learning. RADR® is used to
provide mechanistic insights about drug-tumor interactions, predict
the potential response of cancer types and subtypes to existing
drugs and drug candidates, and uncover patient groups that may
respond to potential therapies being developed by Lantern and its
collaborators.
Contact: Investor Relations
IR@lanternpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-present-at-the-hc-wainwright-bioconnect-2022-conference-301453629.html
SOURCE Lantern Pharma